The debate over the ideal blood glucose target for type 2 diabetics continued this week in the Annals of Internal Medicine, with a group of researchers defending the current recommendations of below 7 percent.
May 25, 2018 | Healthcare Economics
Pfizer gave more than $10 million to a charity for heart patients while dramatically increasing the price of one of its antiarrhythmic drugs, deflecting costs from patients and leaving Medicare with a bigger bill, the U.S. Justice Department said in a May 24 settlement statement.
May 25, 2018 | Hypertension
Total adherence to the 2017 hypertension guidelines would result in about 330,000 fewer deaths each year in the U.S., according to a study published May 23 in JAMA Cardiology.
Individuals with a combination of vascular risk factors and higher levels of beta-amyloid protein in the brain may be on a speedier path of cognitive decline, suggests a study published May 21 in JAMA Neurology.
May 25, 2018 | Practice Management
Philips has reached an agreement with the governments of Ethiopia and the Netherlands to build a €40 million cardiac care facility—the first such specialty hospital in the East African country.
May 24, 2018 | Healthcare Economics
Once more expensive P2Y12 inhibitors hit the U.S. market, the percentage of patients not filling prescriptions for any P2Y12 inhibitor after percutaneous coronary intervention (PCI) increased from 6 percent to 19 percent, researchers reported in JAMA Internal Medicine.
May 24, 2018 | Mobile & Telehealth
Doctor On Demand, a national healthcare service delivered through telehealth technology, has passed one million video visits.
South Asians are more likely to die of atherosclerotic cardiovascular disease, or atherosclerosis, (ASCVD) than East Asians or people of European ancestry, according to a new scientific statement published in the American Heart Association’s journal Circulation on May 24.
A smartwatch algorithm reliably differentiated atrial fibrillation (AF) from sinus rhythm among patients scheduled for elective cardioversion, showing the technology’s potential to prevent unnecessary procedures.
An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.
Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.
May 23, 2018 | Heart Failure
Patients with heart failure who describe themselves as being socially isolated have an increased risk of death and also have an increased use of healthcare resources, according to new research published in the Journal of the American Heart Association on May 23.
Senior citizens who reported exercising at least four times a week throughout their lives showed decreased age-related arterial stiffness when compared to more sedentary individuals, according to a study published May 20 in the Journal of Physiology.
May 23, 2018 | Heart Failure
The FDA has issued a Class I recall of the HeartMate 3 Left Ventricular Assist System (Abbott) because a malfunction in the device’s outflow graft assembly could lead to graft occlusion, possibly reducing or stopping blood flow.
May 23, 2018 | Hypertension
Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.
May 23, 2018 | Practice Management
Pregnancy increases the risk of morbidity in women who exhibit cardiovascular disease (CVD). Complications in expecting mothers may be predicted by a risk index that integrates lesion-specific, delivery-of-care and generic variables.
The FlowTriever System has become the first thrombectomy device designed to treat pulmonary embolism (PE) to be cleared by the FDA, Inari Medical announced in a May 21 press release.
At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.
Two hospitals in East Africa have announced participation in the American College of Cardiology’s CathPCI registry, which aims to assess treatments and outcomes related to cardiac catheterization and percutaneous coronary interventions (PCIs).
Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.
New research from Florida State University suggests depression screening in patients with coronary artery disease (CAD) is especially crucial, because those individuals tend to have higher rates of morbidity and mortality.